Respiratory Distress Syndrome – Pipeline Review, H1 2012

Document Sample
Respiratory Distress Syndrome – Pipeline Review, H1 2012 Powered By Docstoc
					Respiratory Distress Syndrome – Pipeline Review, H1 2012




 Respiratory Distress Syndrome – Pipeline Review, H1
                         2012
                                                                                          Reference Code: GMDHC1702IDB
                                                                                            Publication Date: January 2012




Respiratory Distress Syndrome – Pipeline Review, H1 2012                                   GMDHC1702IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Respiratory Distress Syndrome – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Respiratory Distress Syndrome Overview .......................................................................................................................................... 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Respiratory Distress Syndrome ........................................................................................ 10
Respiratory Distress Syndrome Therapeutics under Development by Companies .......................................................................... 12
Respiratory Distress Syndrome Therapeutics under Investigation by Universities/Institutes............................................................ 14
Late Stage Products ......................................................................................................................................................................... 16
    Comparative Analysis .................................................................................................................................................................. 16
Mid Clinical Stage Products.............................................................................................................................................................. 17
    Comparative Analysis .................................................................................................................................................................. 17
Early Clinical Stage Products ........................................................................................................................................................... 18
    Comparative Analysis .................................................................................................................................................................. 18
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 19
    Comparative Analysis .................................................................................................................................................................. 19
Respiratory Distress Syndrome Therapeutics – Products under Development by Companies ........................................................ 20
Respiratory Distress Syndrome Therapeutics – Products under Investigation by Universities/Institutes ......................................... 21
Companies Involved in Respiratory Distress Syndrome Therapeutics Development ....................................................................... 22
    United Therapeutics Corporation ................................................................................................................................................. 22
    GlaxoSmithKline plc .................................................................................................................................................................... 23
    Discovery Laboratories, Inc. ........................................................................................................................................................ 24
    Pacgen Biopharmaceuticals Corporation .................................................................................................................................... 25
    Advanced Life Sciences Holdings, Inc......................................................................................................................................... 26
    Altor BioScience Corporation....................................................................................................................................................... 27
    NovImmune SA ........................................................................................................................................................................... 28
    Ikaria Inc. ..................................................................................................................................................................................... 29
    Kemin Industries, Inc. .................................................................................................................................................................. 30
    Faron Pharmaceuticals, Ltd. ........................................................................................................................................................ 31
Respiratory Distress Syndrome – Therapeutics Assessment ........................................................................................................... 32
    Assessment by Monotherapy Products ....................................................................................................................................... 32
    Assessment by Combination Products ........................................................................................................................................ 33
    Assessment by Route of Administration ...................................................................................................................................... 34
    Assessment by Molecule Type .................................................................................................................................................... 36
Drug Profiles..................................................................................................................................................................................... 39
    Aviptadil - Drug Profile ................................................................................................................................................................. 39
         Product Description................................................................................................................................................................. 39
         Mechanism of Action ............................................................................................................................................................... 39
         R&D Progress ......................................................................................................................................................................... 39
    ALS-886 - Drug Profile ................................................................................................................................................................ 41



Respiratory Distress Syndrome – Pipeline Review, H1 2012                                                                                      GMDHC1702IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Respiratory Distress Syndrome – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    NI-0101 - Drug Profile.................................................................................................................................................................. 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 42
    SB681323 - Drug Profile .............................................................................................................................................................. 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Aerosurf - Drug Profile ................................................................................................................................................................. 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 45
    Surfaxin - Drug Profile ................................................................................................................................................................. 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    PAC-G31P - Drug Profile ............................................................................................................................................................. 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    ALT-836 - Drug Profile ................................................................................................................................................................. 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50
        R&D Progress ......................................................................................................................................................................... 50
    APN01 - Drug Profile ................................................................................................................................................................... 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    KPE00001175 - Drug Profile ....................................................................................................................................................... 54
        Product Description................................................................................................................................................................. 54
        Mechanism of Action ...............................................................................
				
DOCUMENT INFO
Description: Respiratory Distress Syndrome – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Respiratory Distress Syndrome - Pipeline Review, H1 2012', provides an overview of the Respiratory Distress Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Distress Syndrome. 'Respiratory Distress Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Respiratory Distress Syndrome. - A review of the Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Respiratory Distress Syndrome pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for R
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries